BRPI0517564A - métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica - Google Patents
métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêuticaInfo
- Publication number
- BRPI0517564A BRPI0517564A BRPI0517564-0A BRPI0517564A BRPI0517564A BR PI0517564 A BRPI0517564 A BR PI0517564A BR PI0517564 A BRPI0517564 A BR PI0517564A BR PI0517564 A BRPI0517564 A BR PI0517564A
- Authority
- BR
- Brazil
- Prior art keywords
- adenoma
- adenocarcinoma
- cell
- intestinal
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
MéTODOS PARA MODIFICAR O DESTINO DE UMA CéLULA DE ADENOMA E/OU ADENOCARCINOMA, PARA INDUZIR A FORMAçãO DE UMA CéLULA PóS-MITóTICA A PARTIR DE UM CéLULA DE ADENOMA E/OU ADENOCARCINOMA E PARA, PELO MENOS EM PARTE, DIMINUIR UM ADENOMA E/OU ADENOCARCINOMA INTESTINAL PRESENTE EM UM ANIMAL, USO DE UM INIBIDOR DO TRAJETO DE NOTCH, E, COMPOSIçãO FARMACêUTICA. A invenção refere-se ao campo da bioquímica e medicina. Mais especificamente, a invenção refere-se a métodos e produtos farmacêuticos para o tratamento de um neoplasia intestinal. A invenção descreve a surpreendente descoberta de que inibidores de ativação de trajeto de Notch (por exemplo inibidores de g-secretase) são extremamente úteis no tratamento de adenoma e/ou adenocarcinoma intestinal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04078090 | 2004-11-10 | ||
EP05075806 | 2005-04-06 | ||
PCT/NL2005/000788 WO2006052128A1 (en) | 2004-11-10 | 2005-11-10 | Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0517564A true BRPI0517564A (pt) | 2008-10-14 |
Family
ID=36336759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517564-0A BRPI0517564A (pt) | 2004-11-10 | 2005-11-10 | métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica |
Country Status (11)
Country | Link |
---|---|
US (2) | US20070265246A1 (pt) |
EP (1) | EP1824503A1 (pt) |
JP (1) | JP2008519829A (pt) |
AU (1) | AU2005302846A1 (pt) |
BR (1) | BRPI0517564A (pt) |
CA (1) | CA2586781A1 (pt) |
IL (1) | IL183031A0 (pt) |
NO (1) | NO20072951L (pt) |
NZ (1) | NZ555216A (pt) |
RU (1) | RU2392961C2 (pt) |
WO (1) | WO2006052128A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
BRPI0517564A (pt) * | 2004-11-10 | 2008-10-14 | Hubrecht Lab | métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
EP1795198A1 (en) * | 2005-12-09 | 2007-06-13 | Hubrecht Laboratorium | Treatment of Barret's esophagus |
US7919092B2 (en) * | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
MX2009003229A (es) | 2006-09-29 | 2009-06-18 | Oncomed Pharm Inc | Composiciones y metodos para diagnosticar y tratar cancer. |
US7935791B2 (en) | 2006-12-18 | 2011-05-03 | Genentech, Inc. | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
EP2125887A4 (en) * | 2007-01-24 | 2010-11-10 | Oncomed Pharm Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER |
US8148147B2 (en) | 2007-01-24 | 2012-04-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
WO2008100563A2 (en) * | 2007-02-14 | 2008-08-21 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
PL2307459T3 (pl) | 2008-07-08 | 2015-05-29 | Oncomed Pharm Inc | Czynniki wiążące receptor Notch1 i sposoby ich stosowania |
US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
TWI535445B (zh) * | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
CN102958534B (zh) | 2010-01-13 | 2014-11-05 | 昂考梅德药品有限公司 | Notch1结合剂及其使用方法 |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
RU2622083C2 (ru) * | 2010-12-15 | 2017-06-09 | ВАЙЕТ ЭлЭлСи | Антитела против notch1 |
CN102266587B (zh) * | 2011-07-20 | 2013-12-04 | 山东省眼科研究所 | 一种含杯状细胞的重组眼结膜上皮膜片的制备方法 |
PT2758073T (pt) | 2011-09-23 | 2019-02-01 | Oncomed Pharm Inc | Agentes de ligação a vegf/dll4 e utilizações dos mesmos |
EP2606884A1 (en) * | 2011-12-21 | 2013-06-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
ES2797533T3 (es) * | 2012-02-28 | 2020-12-02 | Novartis Ag | Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43 |
CA2889638A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
TWI582239B (zh) * | 2013-03-11 | 2017-05-11 | 諾華公司 | 與wnt抑制劑相關之標記 |
KR20160104612A (ko) | 2013-07-26 | 2016-09-05 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조성물 |
KR20170029490A (ko) * | 2014-07-11 | 2017-03-15 | 제넨테크, 인크. | 노치 경로 억제 |
ES2808153T3 (es) | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Terapia de combinación para tratamiento de enfermedad |
WO2017053705A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
RU2712302C1 (ru) * | 2019-07-24 | 2020-01-28 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ им. ак. А.М. Гранова" Минздрава России | Способ лечения операбельной аденокарциномы двенадцатиперстной кишки |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19747418C1 (de) * | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
US20030119029A1 (en) * | 1999-04-30 | 2003-06-26 | Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
US8084258B2 (en) * | 1999-07-12 | 2011-12-27 | University Of Basel | Manipulation of tissue of organ type using the notch pathway |
GB0112818D0 (en) * | 2001-05-25 | 2001-07-18 | Lorantis Ltd | Conjugate |
JP2004537314A (ja) * | 2001-07-25 | 2004-12-16 | ロランティス リミテッド | ノッチシグナル伝達モジュレーターを検出する方法 |
WO2003042246A2 (en) * | 2001-11-14 | 2003-05-22 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
CA2501235A1 (en) * | 2002-10-04 | 2004-04-22 | The Regents Of The University Of California | Methods for treating cancer by inhibiting wnt signaling |
CN1777436A (zh) * | 2003-02-18 | 2006-05-24 | 罗斯坎普研究有限责任公司 | β和γ分泌酶抑制剂的抗血管生成和抗肿瘤性 |
WO2004092338A2 (en) * | 2003-04-11 | 2004-10-28 | Diadexus, Inc. | Compositions, splice variants and methods relating to cancer specific genes and proteins |
US20050232927A1 (en) * | 2004-02-03 | 2005-10-20 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
BRPI0517564A (pt) * | 2004-11-10 | 2008-10-14 | Hubrecht Lab | métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica |
CA2591659A1 (en) * | 2004-12-17 | 2006-06-22 | Monash University | Regulation of metalloprotease cleavage of cell surface proteins |
EP1795198A1 (en) * | 2005-12-09 | 2007-06-13 | Hubrecht Laboratorium | Treatment of Barret's esophagus |
-
2005
- 2005-11-10 BR BRPI0517564-0A patent/BRPI0517564A/pt not_active Application Discontinuation
- 2005-11-10 AU AU2005302846A patent/AU2005302846A1/en not_active Abandoned
- 2005-11-10 NZ NZ555216A patent/NZ555216A/en not_active IP Right Cessation
- 2005-11-10 EP EP05810788A patent/EP1824503A1/en not_active Withdrawn
- 2005-11-10 JP JP2007541118A patent/JP2008519829A/ja active Pending
- 2005-11-10 WO PCT/NL2005/000788 patent/WO2006052128A1/en active Application Filing
- 2005-11-10 US US11/667,419 patent/US20070265246A1/en not_active Abandoned
- 2005-11-10 CA CA002586781A patent/CA2586781A1/en not_active Abandoned
- 2005-11-10 RU RU2007121737/14A patent/RU2392961C2/ru not_active IP Right Cessation
-
2007
- 2007-05-07 IL IL183031A patent/IL183031A0/en unknown
- 2007-06-11 NO NO20072951A patent/NO20072951L/no not_active Application Discontinuation
-
2010
- 2010-07-26 US US12/804,699 patent/US20100292165A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1824503A1 (en) | 2007-08-29 |
IL183031A0 (en) | 2007-09-20 |
RU2007121737A (ru) | 2008-12-20 |
US20100292165A1 (en) | 2010-11-18 |
WO2006052128A1 (en) | 2006-05-18 |
JP2008519829A (ja) | 2008-06-12 |
RU2392961C2 (ru) | 2010-06-27 |
NO20072951L (no) | 2007-08-09 |
NZ555216A (en) | 2010-05-28 |
CA2586781A1 (en) | 2006-05-18 |
US20070265246A1 (en) | 2007-11-15 |
AU2005302846A1 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517564A (pt) | métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica | |
CY1109681T1 (el) | Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora | |
AU2007247480A8 (en) | Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID | |
CY1109010T1 (el) | γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ | |
BRPI0510142A (pt) | compostos, composições e métodos para estabilizar a transtiretina e inibir a duplicação defeituosa da transtiretina | |
NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
SE0301700D0 (sv) | Novel compounds | |
EA201001255A1 (ru) | Низкомолекулярные ингибиторы mdm2 и их применения | |
ECSP088561A (es) | Derivados de pirimidinil-aril-urea que son inhibidores de fgf | |
CL2011001536A1 (es) | Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
CY1113141T1 (el) | Απαραβιαστες φαρμακοτεχνικες μορφες δοσολογιας απο του στοματος περιλαμβανουσες ενα οπιουχο αναλγητικο | |
NO20070785L (no) | Sammensetninger for levering av svaert vannloselige medikamenter. | |
BRPI0312464B8 (pt) | compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos | |
NO20090295L (no) | Substituerte heteroarylderivater | |
BRPI0813911A2 (pt) | Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo | |
NO20065936L (no) | Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer. | |
EA200801580A1 (ru) | Новые производные пирониндола и способ их получения | |
BRPI0515721A (pt) | uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação | |
BRPI0713031B8 (pt) | composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos | |
CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
CY1110415T1 (el) | Πρωτοτυπα παραγωγα τετραϋδροκαρβαζολιου με βελτιωμενη βιολογικη δραση και βελτιωμενη διαλυτοτητα, ως συνδετες για υποδοχεις συζευγμενους με πρωτεϊνη g (gpcrs) | |
BRPI0517132B8 (pt) | uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla | |
NO20065898L (no) | 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner | |
PT1282418E (pt) | Utilizacao de derivados pirazolo para o tratamento da infertilidade | |
NO20084190L (no) | Anvendelse av VX-702 til behandling av revmatoid artritt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |